Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Currently, physicians are limited to off-label therapies that have limited evidence to support prescribing. Consequently, there is a pressing need for new, effective drug treatments. With the launch of the first labeled / branded therapy on the horizon, we use claims data to examine how NASH is currently treated in the United States in both newly diagnosed and recently treated patients.
- What patient shares do key off-label therapies garner by line of therapy in newly diagnosed NASH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NASH patients?
- How have off-label therapies, including Intercept Pharmaceuticals’ Ocaliva, been integrated into the treatment algorithm, and what is their source of business?
- What percentage of NASH patients receive off-label drug therapy within a year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of NASH patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION: Treatment Algorithms:Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
GEOGRAPHY: United States
REAL WORLD DATA: Longitudinal patient-level claims data analysis
KEY DRUGS COVERED: Ocaliva (obeticholic acid), pioglitazone, vitamin E, metformin, ursodeoxycholic acid, statins, SGLT-2 inhibitors, GLP-1 receptor agonists
KEY ANALYSIS PROVIDED: Brand/therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts.
- Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms: Claims Data Analysis | Nonalcoholic Steatohepatitis (NASH) | US | March 2020
Author(s): Rohit Bansal, MS (Pharm.)
Rohit joined Decision Resources Group (DRG)’s Cardiovascular, Metabolic, Renal, and Hematologic Disorders team in April 2019. His current focus includes non-alcoholic steatohepatitis (NASH), glomerulonephritis, and renal anemia. Prior to joining DRG, Rohit worked as analyst helping pharmaceutical clients address their business questions across various therapeutic areas. Rohit’s postgraduate research centred on molecular dynamics. His work included computer-aided drug design software that involved studying the effect of pharmaceutical excipients on the reabsorption of drug molecules from cancer cells leading to drug resistance.